Seres Therapeutics (MCRB) & Its Peers Head to Head Comparison

Seres Therapeutics (NASDAQ:MCRB) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Seres Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Seres Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Seres Therapeutics Competitors	-9,051.23%	-201.20%	-30.64%

Risk & Volatility

Seres Therapeutics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Seres Therapeutics’ peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares Seres Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seres Therapeutics	$1.88 million	$5.70 million	-0.86
Seres Therapeutics Competitors	$727.61 million	$12.25 million	-10.38

Seres Therapeutics’ peers have higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Seres Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1	1	2	0	2.25
Seres Therapeutics Competitors	9791	15070	45345	1572	2.54

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 713.40%. As a group, “Biotechnology” companies have a potential upside of 93.57%. Given Seres Therapeutics’ higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than its peers.

Summary

Seres Therapeutics peers beat Seres Therapeutics on 8 of the 13 factors compared.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.